Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer

Endocrine-resistance remains a major challenge in estrogen receptor α positive (ERα(+)) breast cancer (BC) treatment and constitutively active somatic mutations in ERα are a common mechanism. There is an urgent need to develop novel drugs with new mode of mechanism to fight endocrine-resistance. Giv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yubo, Min, Jian, Deng, Xiangping, Feng, Tian, Hu, Hebing, Guo, Xinyi, Cheng, Yan, Xie, Baohua, Yang, Yu, Chen, Chun-Chi, Guo, Rey-Ting, Dong, Chune, Zhou, Hai-Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692362/
https://www.ncbi.nlm.nih.gov/pubmed/38045063
http://dx.doi.org/10.1016/j.apsb.2023.05.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692362/
https://www.ncbi.nlm.nih.gov/pubmed/38045063
http://dx.doi.org/10.1016/j.apsb.2023.05.005

Ejemplares similares